A clinical trial for zoledronic acid added into new adjuvant chemotherapy on osteosarcoma patients

The efficacy of new adjuvant chemotherapy of osteosarcoma combined with zoledronic acid in decrease the lung metastatic rate of osteosarcoma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16008568

Enrollment

Unknown

Registered

2016-05-31

Start date

2016-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteosarcoma

Interventions

group 1:zoledronate

group 2:placebo

Eligibility

Sex/Gender

All

Age

5 Years to 80 Years

Inclusion criteria

Inclusion criteria: primary, diagnosed as osteosarcoma by pathology, screen out distant metastases by chest CT and bone ECT, assessed the patient can accept the standard chemotherapy for osteosarcoma.

Exclusion criteria

Exclusion criteria: Diagnosed as lung metastases at primary, pregnant patient, Renal insufficiency, Liver dysfunction, obvious oral disease, not suitable for the treatment of bisphosphonate after the assessment, accompanied by a disease that still need to be treated with hormone therapy, abnormal of blood system, heart disease

Design outcomes

Primary

Measure	Time frame
Progression free survival;	—

Secondary

Measure	Time frame
lung metastasis rate;prothesis survival rate;	—

Countries

China

Contacts

Public ContactZhaoming YE

2nd Affiliated Hospital, ZheJiang University

yezhaominghz@163.com+86 13606501549

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026